Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | FDFT1 | P37268 | 3/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | CETP | P11597 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9538055 | 0.87 | TAAR1 (0.56) | PNMTFDFT1TAAR1PPARGPPARA | |
| SCHEMBL13719088 | 0.86 | PPARG (0.59) | PNMTFDFT1TAAR1PPARGPPARA | |
| SCHEMBL13719005 | 0.83 | TAAR1 (0.46) | PNMTFDFT1TAAR1PPARGPPARA | |
| SCHEMBL16316249 | 0.82 | KMO (0.51) | KMOFDFT1HSP90AA1HTR2ASLC6A4 | |
| SCHEMBL8174800 | 0.82 | CETP (0.54) | FDFT1TAAR1PPARGPPARACETP | |
| SCHEMBL13718930 | 0.81 | TAAR1 (0.60) | TAAR1PPARGPPARASLC6A4CETP | |
| SCHEMBL13718948 | 0.81 | FFAR1 (0.48) | FDFT1TAAR1PPARGPPARACETP | |
| SCHEMBL19002457 | 0.81 | KMO (0.48) | KMOPNMTFDFT1PPARGPPARA | |
| SCHEMBL8171976 | 0.79 | CETP (0.47) | FDFT1TAAR1PPARGPPARACETP | |
| SCHEMBL4160110 | 0.79 | KMO (0.51) | KMOFDFT1PPARGPPARAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | KMO 2649/4885PNMT 2176/4885FDFT1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.